Open AccessBendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
Author(s) -
Suzanne Lentzsch,
Galina Lagos,
Raymond L. Comenzo,
Jeffrey A. Zonder,
Keren Osman,
Samuel Pan,
Divaya Bhutani,
Silva Pregja,
Vaishali Sanchorawala,
Heather Landau
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01721
Subject(s) - medicine , bendamustine , al amyloidosis , nausea , dexamethasone , adverse effect , multiple myeloma , gastroenterology , refractory (planetary science) , amyloidosis , vomiting , surgery , phases of clinical research , progressive disease , chemotherapy , lymphoma , rituximab , immunoglobulin light chain , immunology , physics , antibody , astrobiology
No established treatments exist for relapsed/refractory systemic light-chain (AL) amyloidosis. Bendamustine has shown potential in the treatment of multiple myeloma. We conducted a phase II, multicenter trial to assess the efficacy and safety of bendamustine with dexamethasone (ben-dex) in patients with persistent or progressive AL amyloidosis after ≥ 1 prior therapy.